Sofinnova Partners Leads $34.5 Mln Round for ObsEva

ObsEva said Thursday that it closed a CHF 32 million (US$34.5 million) series A financing round led by Sofinnova Partners, and co-led by Sofinnova Ventures and Novo A/S. ObsEva also signed a licensing agreement with Merck Serono. As part of the deal, MS Ventures, Merck Serono's corporate venture fund, has taken a minority stake in ObsEva. Geneva-based ObsEva is a speciality biopharmaceutical company that is developing drugs for women's reproductive medicine.

North AmericaUSBriefs